-The Hindu   Every day, more than 5,000 people develop tuberculosis; nearly three lakh children drop out of school owing to the disease and more than one lakh women are rejected by families in India. A middle-aged patient with a history of cough with blood-tinged sputum for three weeks duration consults a doctor. The physician puts forth a routine query whether anyone in his family suffers/suffered from tuberculosis? Annoyed, the patient responds: no...

-The Hindu     Aim is to help urban poor go to health facilities after working hours To help urban poor go to health facilities after working hours, urban primary health centres, planned under the National Urban Health Mission (NUHM), will function from noon to 8 p.m. Out-patient departments at standard health facilities worked only in the morning; when patients had to go to work, visiting a doctor or hospital would mean losing a...

-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...

-Frontline   The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...